All News
Filter News
Found 77 articles
-
Eli Lilly Projects 20 New Product Launches in 10 Years with 20 Possible Expansions
5/25/2016
-
Eli Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance
4/26/2016
-
Two Under-the-Radar Updates Pfizer Investors Need to Know About
5/7/2015
-
Pfizer Pockets $200 Million as Tanezumab Phase III Program With Eli Lilly Resumes
3/23/2015
-
Eli Lilly Provides Update On Strategy And Announces 2015 Financial Guidance
1/7/2015
-
Eli Lilly and Company Projects Spot-On '14 Profit Slump
1/7/2014
-
GlobalData Release: Osteoarthritis Pain Medications Struggle to Impress in Advanced Cases
6/8/2012
-
Tanezumab Helps OA, but Trials Stopped
9/30/2010
-
Tanezumab Helps Osteoarthritis, But Trials Stopped, University of California, Davis (UCD) Study
9/30/2010
-
Urigen Pharmaceuticals, Inc. Announces FDA Follow Up
8/11/2010
-
Pfizer Inc. Halts Tanezumab Studies For Back Pain, Diabetes
7/21/2010
-
Trial and Errors: Pfizer Inc.'s Drug Failures Are the Result of Bad Management, Not Clinical Misfortune
6/25/2010
-
Pfizer Inc. Halts Clinical Trials of Arthritis Drug, Tanezumab
6/24/2010
-
Pfizer Inc. (JOBS) Drops 100 Drugs from Pipeline
1/29/2010
-
Pfizer Inc. Drops Development of 2 Late-Stage Drugs
2/24/2009
-
XOMA (US) LLC Receives Milestone Payment From Pfizer Inc. Under Antibody Technology License
1/22/2009
-
Pfizer Inc. to Present Data on New Approaches to Pain and Inflammation Treatment at American College of Rheumatology Meeting
10/27/2008